No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Transcenta Holding Limited is a clinical-stage biopharmaceutical company focused on the discovery, research, development, manufacturing, and commercialization of therapeutic agents within the People's Republic of China and the United States. The company boasts a comprehensive pipeline of drug candidates. In oncology, its key developments include: MSB2311, a humanized PD-L1 monoclonal antibody, currently in Phase Ib/IIa trials for various solid tumors, particularly those with high tumor mutational burden (TMB-H). TST001, a humanized claudin 18.2 monoclonal antibody undergoing Phase II clinical development for solid tumors, such as gastric cancer. TST005, a bifunctional PD-L1/TGF-ß antibody in Phase Ia clinical trials for solid tumors, including certain types of lung cancer. TST010, an antibody designed to target regulatory T cells, aiming to bolster T cell-mediated anti-tumor activity. TST003, an antibody addressing a novel immune regulatory protein produced by tumor-associated fibroblasts or tumor cells exhibiting a mesenchymal phenotype. TST006, a bispecific antibody targeting both claudin 18.2 and PD-L1. TST008, a trifunctional antibody that combines a MASP2 antibody with a truncated transmembrane activator and CAML interactor protein. MSB0254, a humanized VEGFR-2 monoclonal antibody also in Phase Ib/IIa clinical studies for solid tumors. Beyond cancer, Transcenta is advancing: TST002 (Blosozumab), a humanized sclerostin monoclonal antibody for the treatment of osteoporosis. TST004, a humanized mannan-binding lectin serine protease 2 (MASP 2) monoclonal antibody intended for IgA kidney diseases. The company has forged collaboration agreements with prominent organizations, including Eli Lilly and Company, Alebund Pharmaceuticals, and Merck. Founded in 2010 as MabSpace International Limited, the entity adopted the name Transcenta Holding Limited in June 2019. Its corporate headquarters are located in Suzhou, People's Republic of China.

• Gwo Xi Stem Cell Applied Technology Co. , Ltd
• Poolbeg Pharma PLC
• iNtRON Biotechnology, Inc.
• Synthaverse S.A.
• NRx Pharmaceuticals, Inc.
• OKYO Pharma Limited
• INmune Bio, Inc.
• Xilio Therapeutics, Inc.